IPG 001
Alternative Names: IPG-001Latest Information Update: 05 Jan 2022
At a glance
- Originator Nanjing Amifei Biopharmaceutical Technology
- Developer Immunophage Biotech; Nanjing Amifei Biopharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Autoimmune disorders; Breast cancer; Liver cancer; Multiple sclerosis; Systemic lupus erythematosus
Most Recent Events
- 16 Dec 2021 IPG 001 is available for licensing as of 16 Dec 2021. http://www.immunophage.com.cn/yanfaguanxian.html
- 16 Dec 2021 Clinical trials in Autoimmune disorders in China (unspecified route) (Immunophage Biotech pipeline, December 2021)
- 16 Dec 2021 Clinical trials in Breast cancer in China (unspecified route) (Immunophage Biotech pipeline, December 2021)